Product Information
STEGLUJAN 15-100 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $17.5864 per EA under NDC 00006536806. Its NADAC has been published 350 times since Jan 22, 2020.
FDA first approved this application on Dec 19, 2017.
Strength
15; 100 mg/1; mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006536806
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERTUGLIFLOZIN PIDOLATE; SITAGLIPTIN PHOSPHATEApproval Type
New Drug (NDA)
FDA Application
NDA209805FDA Approved
12/19/2017
On Market Since
12/19/2017
Pharmacological Classes
Price Statistics
The NADAC for STEGLUJAN 15-100 MG TABLET has been published 350 times since Jan 22, 2020, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.5864 per EA |
|---|---|
| All-time high | $17.7538 (Jul 16, 2025) |
| All-time low | $17.5337 (Nov 18, 2020) |
| 52-week high | $17.7187 |
| 52-week low | $17.5370 |
| Median price | $17.6256 |
| Average price | $17.6364 |
| Largest weekly change | -0.6% (Jan 21, 2026) |
| Weeks tracked | 350 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ertugliflozin and sitagliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of STEGLUJAN 15-100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for STEGLUJAN 15-100 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $17.5864 per EA (NDC 00006536806), effective Sep 30, 2026.
How has the price of STEGLUJAN 15-100 MG TABLET changed over time?
Over the history we have for it, the NADAC for STEGLUJAN 15-100 MG TABLET has held within roughly two percent of its current level. It has been tracked across 350 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for STEGLUJAN 15-100 MG TABLET?
Since Jan 22, 2020, the NADAC for STEGLUJAN 15-100 MG TABLET has ranged from a low of $17.5337 (Nov 18, 2020) to a high of $17.7538 (Jul 16, 2025), with a median of $17.6256 per EA.
Are there cheaper alternatives to STEGLUJAN 15-100 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as STEGLUJAN 15-100 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures STEGLUJAN 15-100 MG TABLET?
STEGLUJAN 15-100 MG TABLET (NDC 00006536806) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.